Patient responses to nasal high flow therapy (PRNHFT): a pilot study

Not Applicable

Not yet recruiting

• Conditions: Respiratory distress; Respiratory - Other respiratory disorders / diseases

• Registration Number: ACTRN12620000378921
• Lead Sponsor: Fisher & Paykel Healthcare

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-03-19
• Last Update Posted: 23 March 2020

Recruitment & Eligibility

• Status: Not yet recruiting
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:
1.Provision of signed and dated informed consent form
2.Stated willingness to comply with all study procedures and availability for the duration of the study
3.Male or female, aged > 16 years
4.Ability to tolerate the therapy and be willing to adhere to the study intervention regimen
5.Agreement to adhere to therapy considerations throughout study duration

Exclusion Criteria

An individual who meets any of the following criteria will be excluded from participation in this study:

1.Pregnancy or lactation
2.Known allergic reactions to, or contraindications to components of the study intervention
3.Involvement in another investigational study at the same time i.e. simultaneously

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in patients physiology (respiratory) <br><br>SpO2 as assessed by pulse oximetry[For each % FiO2 therapy change - maximum duration of ten days (whilst on AIRVO therapy but expected to be 48Hours based on historical data))<br>FiO2 therapy change frequency as determined by clinical need and cannot be predicted ];Change in patients physiology (respiratory) <br>Respiratory rate as assessed by monitoring clinician<br>[For each % FiO2 therapy change - maximum duration of ten days (whilst on AIRVO therapy but expected to be 48Hours based on historical data))<br>FiO2 therapy change frequency as determined by clinical need and cannot be predicted ]

Secondary Outcome Measures

Name	Time	Method
Change in patients physiology (cardiac):<br>Blood pressure as assessed by bench-top sphygmomanometer and or in line arterial monitor if available[For each % FiO2 therapy change - maximum duration of ten days (whilst on AIRVO therapy but expected to be 48Hours based on historical data))<br>FiO2 therapy change frequency as determined by clinical need and cannot be predicted <br>];Change in patients physiology (cardiac):<br>Heart rate as assessed by infrared pulse oximeter<br>[For each % FiO2 therapy change - maximum duration of ten days (whilst on AIRVO therapy but expected to be 48Hours based on historical data))<br>FiO2 therapy change frequency as determined by clinical need and cannot be predicted ]